close
References
  1. Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903-912.
  2. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91-101.
  3. Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(Suppl 1):10S-16S.
  4. Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623-633.
  5. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
  6. Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839-846.
  7. Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immuno. 2019;122(5):449-455.
  8. Wei W, Anderson P, Gadkari A, et al. Discordance between physician- and patient-reported disease severity in adults with atopic dermatitis: a US cross-sectional survey. Am J Clin Dermatol. 2017;18(6):825-835.
  9. Spuls PI, Gerbens LAA, Simpson E, et al; HOME initiative collaborators. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176(4):979-984.
  10. Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2020;36(3):367-376.
  11. Brunner PM, Guttman-Yassky E, Leung DYM. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65-S76.
  12. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122.
  13. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018;27(4):409-417.
  14. Kim JE, Kim JS, Cho DH, Park HJ. Molecular mechanisms of cutaneous inflammatory disorder: atopic dermatitis. Int J Mol Sci. 2016;17(8):1234.
  15. Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018;141(5):1677-1689.
  16. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-862.
  17. Van Laethem F, Baus E, Smyth LA, et al. Glucocorticoids attenuate T cell receptor signaling. J Exp Med. 2001;193(7):803-814.
  18. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
  19. Prescribing information. Astellas Pharma US, Inc. 2011.
  20. Prescribing information. Valeant Pharmaceuticals North America LLC. 2014.
  21. Prescribing information. Pfizer Labs. 2020
  22. Dupilumab prescribing information. Regeneron Pharmaceuticals, Inc. 2020.
  23. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  24. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  25. Thaci D, Deleuran M, Bissonnette R, et al. P01. Safety and efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE). Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  26. Blauvelt A, Guttman-Yassky E, Hussain I, et al. P05. Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE). Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  27. Paller AS, Siegfried EC, Gooderham M, et al. P50. Dupilumab significantly improves atopic dermatitis in children aged ≥6 to <12 years: results from phase 3 trial (LIBERTY AD PEDS). Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  28. Beck LA, Simpson EL, Hong C, et al. P03. Dupilumab offers early and sustained improvement in sleep in adolescents with moderate-to-severe dermatitis. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  29. Simpson EL, Gadkari A, Beck LA, et al. P02. Dupilumab offers rapid improvement in pruritus in adolescents with moderate-to-severe atopic dermatitis vs placebo: a post-hoc analysis of a phase III trial. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  30. Simpson EL, Flohr C, Eichenfield LE, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863-871.e11.
  31. Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis. A phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411-420.
  32. Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135-141.
  33. Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182.
  34. Silverberg J, Simpson EL, Thyssen JP, et al. P12. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III JADE MONO-2 study. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  35. Simpson EL, Stander S, Yosipovitch G, et al. P11. Peak Pruritus Numerical Rating Scale response with abrocitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized, phase III clinical trial. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  36. Gooderham MJ, Girolomoni G, Moore JO, et al. P23. Predictors of maintenance of response in patients with moderate-to-severe atopic dermatitis after interruption of the oral Janus kinase 1-selective inhibitor abrocitinib interruption. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  37. Reich K, Lacour JP, Costanzo A, et al. Safety of baricitinib in patients with atopic dermatitis: results of pooled data from two phase III monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and BREEZE-AD2). Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  38. Simpson EL, Thyssen JP, Bissonnette R, et al. P36. Rapid and concurrent improvements in signs and symptoms of atopic dermatitis with baricitinib in phase III studies. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  39. Simpson E, Forman S, Silverberg J, et al. Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5). Br J Dermatol. 2020.
  40. Silverberg J, Reich K, Calimlim B, et al. P08. Achieving an itch-free state with upadacitinib: a post-hoc analysis of data from a phase IIb randomized, double-blind, placebo-controlled trial in moderate-to-severe atopic dermatitis. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  41. Reich K, Thaci D, Papp K, et al. P09. Treatment withdrawal and retreatment with upadacitinib in patients with moderate-to-severe atopic dermatitis from a phase IIb, randomized, controlled trial. Revolutionizing Atopic Dermatitis Virtual Symposium. Br J Dermatol. 2020.
  42. Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME; INCB 18424-206 Study Investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572-582.
  43. Incyte Corporation. Incyte announces positive topline results from phase 3 TRuE-AD program evaluating ruxolitinib cream in patients with atopic dermatitis. February 19, 2020.
  44. LeBovidge J, Borok J, Udkoff J, Yosipovitch G, Eichenfield LF. Atopic dermatitis: therapeutic care delivery: therapeutic education, shared decision-making, and access to care. Semin Cutan Med Surg. 2017;36(3):131-136.
  45. Eichenfield LF, Ahluwalia J, Waldman A, Borok J, Udkoff J, Boguniewicz M. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49-S57.
  46. Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519-1531.
  47. American College of Allergy, Asthma, and Immunology. Controlling your eczema (atopic dermatitis). https://acaai.org/controlling-your-eczema-atopic-dermatitis. Accessed on June 28, 2020.